Assenagon Asset Management S.A. Has $171.37 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Assenagon Asset Management increased its Thermo Fisher Scientific stake by 83.3% in the second quarter, holding 341,813 shares worth approximately $171.4 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly earnings of $6.03 per share, beating estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $619.41, compared with the stock’s reported price of $579.85. Thermo Fisher also declared a quarterly dividend of $0.47 per share, yielding approximately 0.3%.

Assenagon Asset Management S.A. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 83.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 341,813 shares of the medical research company's stock after buying an additional 155,377 shares during the quarter. Assenagon Asset Management S.A. owned 0.09% of Thermo Fisher Scientific worth $171,371,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. J. Stern & Co. LLP boosted its stake in Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. Norges Bank bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $3,072,744,000. Auto Owners Insurance Co boosted its position in shares of Thermo Fisher Scientific by 57,845.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock valued at $1,406,844,000 after acquiring an additional 2,423,706 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in Thermo Fisher Scientific by 2,183.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company's stock worth $770,000,000 after purchasing an additional 1,270,643 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Thermo Fisher Scientific by 19.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company's stock worth $4,462,550,000 after purchasing an additional 1,230,872 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $579.85 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The stock has a 50-day simple moving average of $515.61 and a 200 day simple moving average of $510.03. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $214.40 billion, a price-to-earnings ratio of 31.19, a P/E/G ratio of 2.35 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter last year, the company posted $4.28 EPS. The company's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TMO shares. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective for the company. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 price objective for the company. Finally, Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source